10-K: Chain Bridge I Faces Delisting, Liquidity Concerns Amid Search

Chain Bridge I, a blank check company, reported recurring losses, a working capital deficit, and delisting from Nasdaq to OTCID, raising substantial doubt about its ability to continue as a going concern.

Summary

• Chain Bridge I is a blank check company formed to effect a business combination, with no operating history or revenues to date.
• The company has extended its deadline to consummate an initial business combination multiple times, with the current deadline set for November 15, 2026.
• A previously announced business combination agreement with Phytanix Bio was mutually terminated on April 7, 2025.
• The company's securities were delisted from Nasdaq and now trade on the OTCID Basic Market due to non-compliance with public float requirements.
• As of December 31, 2025, the company reported a net loss of approximately $1.3 million and a working capital deficit of $808,537.
• The company's auditor has raised substantial doubt about its ability to continue as a going concern due to liquidity issues and the mandatory liquidation date.
• Significant shareholder redemptions have occurred in connection with extension votes, reducing the funds in the trust account.
• The company relies on loans from related parties (Fulton AC, C/M Capital Master Fund LP) to fund its operations and search for a business combination.
• Management identified a material weakness in internal control over financial reporting related to the adequate review and reconciliation of liabilities and prepaid expenses as of December 31, 2025.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing with a highly negative sentiment due to the company's ongoing inability to complete a business combination, significant financial distress, delisting from Nasdaq, and the auditor's 'going concern' warning, indicating a high risk of liquidation.

Positives

• The company successfully obtained shareholder approval to extend the business combination deadline to November 15, 2026.
• Fulton AC has agreed to reimburse the Trust Account up to $100,000 for dissolution expenses if the company is dissolved.
• Fulton AC has made monthly contributions to the Trust Account to support extensions, totaling $52,500 in additional contributions for the year ended December 31, 2025.

Negatives

• The company reported a net loss of approximately $1.3 million for the year ended December 31, 2025, and $1.4 million for the year ended December 31, 2024.
• A working capital deficit of $808,537 as of December 31, 2025, indicates insufficient funds for current operations.
• The company's securities were delisted from Nasdaq and now trade on the less liquid OTCID Basic Market, which may adversely affect investors' ability to resell securities.
• The business combination agreement with Phytanix Bio was mutually terminated on April 7, 2025, requiring the company to restart its search for a target.
• Substantial doubt about the company's ability to continue as a going concern has been raised by the auditor.
• Significant shareholder redemptions occurred, with $4,761,252 in cash redeemed in October 2025 and $34.5 million in February 2024, reducing the trust account balance.
• A material weakness in internal control over financial reporting was identified as of December 31, 2025, related to the review and reconciliation of liabilities and prepaid expenses.

Risks

• The company is a recently incorporated blank check company with no operating history or revenues, providing no basis to evaluate its ability to achieve its business objective.
• Past performance by the management team or affiliates may not be indicative of future performance.
• Public shareholders may not have an opportunity to vote on the proposed initial business combination, and a majority of shareholders may not support it.
• The ability of public shareholders to redeem shares for cash may make the company's financial condition unattractive to potential business combination partners.
• The requirement to consummate an initial business combination by November 15, 2026, may give potential partners leverage and limit due diligence time.
• The search for a business combination may be adversely affected by military conflicts, terrorism, sanctions, geopolitical events, pandemics, and the status of debt and equity markets.
• Failure to consummate an initial business combination by November 15, 2026, would result in liquidation, with public shareholders receiving approximately $12.37 per share (as of March 27, 2026) and warrants expiring worthless.
• Fulton AC and other insiders have agreed to vote in favor of an initial business combination, potentially influencing the outcome regardless of public shareholder sentiment.
• Changes in the market for directors and officers liability insurance could make it more difficult and expensive to complete a business combination.
• Shareholders may not receive notice of redemption offers or may fail to comply with tendering procedures, leading to unredeemed shares.
• Funds in the trust account could be reduced by third-party claims, potentially leading to a per-share redemption amount less than $10.20.
• The company may be deemed an investment company under the Investment Company Act, requiring burdensome compliance or liquidation.
• Changes in laws or regulations, or non-compliance, may adversely affect the business.
• Shareholders may face difficulties protecting their interests due to the company's incorporation under Cayman Islands law.
• Provisions in the company's articles of association may inhibit a takeover, limiting future share price and entrenching management.
• Cyber incidents or attacks could result in information theft, data corruption, operational disruption, and financial loss.
• Acquiring and operating a business in foreign countries presents additional risks, including regulatory, economic, political, and currency fluctuation risks.
• The company may issue additional Class A ordinary shares or preference shares, diluting existing shareholders' interests.
• Resources could be wasted on uncompleted acquisitions, adversely affecting subsequent attempts.
• The company may reincorporate in another jurisdiction, potentially resulting in taxes for shareholders.
• Executive officers and directors allocate time to other businesses, creating conflicts of interest.
• The company may issue notes or incur substantial debt to complete a business combination, adversely affecting leverage and financial condition.
• Lack of business diversification after a single business combination may negatively impact operations and profitability.
• Limited ability to evaluate a partner's management team may lead to an unsuccessful combination.
• The company may seek complex acquisition opportunities requiring significant operational improvements, which could be delayed or unsuccessful.
• The absence of a specified maximum redemption threshold may allow completion of a business combination that a substantial majority of shareholders do not agree with.
• The company may amend its charter or warrant agreements to facilitate a business combination that shareholders may not support.
• The company may be unable to obtain additional financing to complete a business combination or fund operations, leading to restructuring or abandonment.
• Fulton AC holds a substantial interest (52.21% voting power as of March 27, 2026) and may exert significant influence on shareholder votes.
• The company may redeem unexpired warrants prior to their exercise at a disadvantageous time, making them worthless.
• Warrants accounted for as a liability may adversely affect the market price of Class A ordinary shares or make it harder to consummate a business combination.
• The warrant agreement designates specific courts as the sole forum for certain actions, potentially limiting warrant holders' ability to obtain a favorable judicial forum.
• Each unit contains one-half of one warrant, which may make units worth less than those of other blank check companies.
• The company may lose the ability to complete an advantageous business combination if a prospective partner cannot provide required financial statements in time.
• As an emerging growth company and smaller reporting company, reliance on exemptions may make securities less attractive and comparisons difficult.

Future Outlook

The company's future outlook is highly uncertain, contingent on its ability to identify and successfully complete an initial business combination by November 15, 2026. Management intends to continue leveraging its team's network and expertise to find a growth-oriented, market-leading company. However, the company acknowledges the significant challenges posed by its limited operating history, recurring losses, and the competitive SPAC market. If a business combination is not consummated, the company will liquidate, and public shareholders will receive a pro rata distribution from the trust account, while warrants will expire worthless.

Management Comments

• Our efforts have been limited to organizational activities as well as activities related to the Initial Public Offering.
• While we have not selected a target for a business combination, our team has identified several potential target companies that it believes are compelling opportunities for a business combination.
• There are ongoing discussions about the suitability of those potential target companies and we have commenced discussions with several such companies directly and through intermediaries.
• We have generated no operating revenues to date, and we do not expect that we will generate operating revenues until we consummate our initial business combination.
• We believe that our success depends on the continued service of our officers and directors, at least until we have completed our initial business combination.
• Management has undertaken remediation steps to address the material weakness, including increasing management review processes over liabilities. This remediation is an ongoing process and there can be no assurance that it will effectively address the material weaknesses.

Industry Context

StockSavvy.ai notes that Chain Bridge I's situation reflects broader challenges within the SPAC market, particularly for those that have struggled to identify and close a business combination within their initial timelines. The delisting from Nasdaq to OTCID is a common outcome for SPACs that fail to complete a de-SPAC transaction, significantly reducing liquidity and investor confidence. The termination of the Phytanix Bio agreement, coupled with multiple deadline extensions and substantial shareholder redemptions, highlights the intense competition for attractive targets and the difficulty in executing complex transactions in a volatile economic environment. The reliance on related-party financing and the 'going concern' warning are critical indicators of the heightened risk profile compared to more established operating companies or successful SPACs like GSR II Meteora Acquisition Corp. (which completed its business combination with Bitcoin Depot Inc.).

Comparison to Industry Standards

• Unlike successful SPACs such as GSR II Meteora Acquisition Corp. (which completed its initial business combination with Bitcoin Depot Inc. in Q2 2023), Chain Bridge I has failed to complete a business combination and has terminated a previously announced deal.
• The delisting from Nasdaq to OTCID places Chain Bridge I in a less liquid market, a stark contrast to companies that maintain major exchange listings post-de-SPAC, such as NKGen Biotech Inc. (NASDAQ: NKGN) which resulted from a Graf Acquisition Corp. IV SPAC transaction.
• The recurring need for deadline extensions and related-party financing (e.g., Fulton AC Note, Bridge Financing Note, C/M Note) indicates a prolonged and challenging search process, unlike SPACs that secure targets more efficiently.
• The significant shareholder redemptions (e.g., $197.8 million in May 2023, $34.5 million in February 2024, $6.3 million in November 2024, $4.7 million in October 2025) are substantially higher than typical redemption rates for successful SPACs, reflecting a lack of investor confidence in the company's ability to find a suitable target or execute a value-creating transaction.
• The company's current cash balance of $390,255 and working capital deficit of $808,537 as of December 31, 2025, are significantly lower than the capital typically available to SPACs actively pursuing substantial business combinations, making it less competitive against other blank check companies or strategic acquirers.

Management Changes

Corporate Governance

Legal Proceedings

• No material litigation, arbitration, or governmental proceeding is currently pending against the company or its management.

Related Party Transactions

• Fulton AC, CBG, and CB Co-Investment are significant related parties, involved in initial share issuance, warrant purchases, and various loans.
• Fulton AC acquired 3,035,000 Class B ordinary shares and warrants to purchase 7,385,000 Class A ordinary shares from CBG and CB Co-Investment on December 29, 2023.
• CB Co-Investment agreed to convert a $1.15 million loan into contingently issuable Private Placement Warrants upon business combination.
• Fulton AC provided a working capital loan of up to $1.5 million (Fulton AC Note), later exchanged for the Exchange Note, which had an outstanding balance of $368,680 as of December 31, 2025.
• The company pays Fulton AC up to $30,000 per month for office space, administrative, and support services.
• Fulton AC agreed to reimburse the Trust Account up to $100,000 for dissolution expenses.
• Fulton AC has made monthly contributions to the Trust Account to extend the company's life.
• RSU awards were granted to directors Mr. Silberman, Mr. Baron, and Mr. Wiener, and a former CFO Mr. Lazarus, contingent on a business combination and shareholder approval of an incentive plan.
• Andrew Kucharchuk, CFO, is compensated via a consulting agreement with Fulton AC.
• Fulton AC, CBG, CB Co-Investment, and current/former directors and officers have waived redemption rights and liquidation rights for their Class B shares and certain public shares.

Stakeholder Impact

• Shareholders face significant risk of investment loss if a business combination is not completed by November 15, 2026, as warrants will expire worthless and redemptions may be less than anticipated due to creditor claims.
• Public shareholders have experienced substantial dilution and reduced liquidity due to delisting from Nasdaq to OTCID and significant redemptions.
• Creditors may have claims against the trust account, potentially reducing the per-share redemption amount for public shareholders.
• Management and directors, particularly Fulton AC, hold significant control and have financial interests tied to the completion of a business combination, potentially creating conflicts of interest.
• Employees (executive officers) are few and their compensation and future roles are largely contingent on the successful completion of a business combination.

Next Steps

• Continue the search for a suitable business combination partner.
• Address the material weakness in internal control over financial reporting by increasing management review processes over liabilities.
• Actively evaluate strategic options to regain compliance with relevant listing standards for OTCQB, including increasing public float to at least 10% of total shares outstanding.
• Potentially seek further extensions for the business combination deadline beyond November 15, 2026, subject to shareholder approval (though the company does not currently intend to do so).
• If a business combination is not consummated by November 15, 2026, the company will cease operations, redeem public shares, and liquidate.

Key Dates

Recommendation

The company faces severe existential threats, including a 'going concern' warning from its auditor, recurring net losses, a significant working capital deficit, and a history of failed business combinations and substantial shareholder redemptions. The delisting from Nasdaq to the illiquid OTCID market further diminishes investor value and future capital-raising prospects. While management has secured extensions and related-party financing, these measures appear to be delaying an inevitable liquidation rather than signaling a viable path to a successful business combination. The high risk of warrants expiring worthless and the potential for public shareholders to receive less than the estimated redemption value due to creditor claims make this a 'strong sell' for any remaining investors.

Keywords

SPAC, Blank Check Company, Business Combination, SEC Filing, 10-K, Financial Reporting, Corporate Governance, Risk Factors, Liquidity, Going Concern, Delisting, OTCID, Shareholder Redemptions, Warrants, Fulton AC, Phytanix Bio, Capital Raise, Internal Controls, Cayman Islands, Emerging Growth Company